Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

HémopressineHemopressin (Hp, PVNFKFLSH)

A haemoglobin nonapeptide, a selective CB1 inverse agonist; its endogenous existence is contested.

Level of detail

C₅₃H₇₇N₁₃O₁₂

CAS 568588-77-2

Family
Endocannabinoid or related mediatorPeptide ligand
Molar mass
1,088.30 g/mol

Updated on

In plain terms

Hemopressin is a small peptide fragment derived from haemoglobin, the pigment that carries oxygen in the blood. Its distinctive feature is that it blocks the CB1 receptor, the very one THC activates. Whether it really exists in the body remains disputed: the established endogenous form of this family is a longer peptide, RVD-hemopressin.

Receptors and activity

Target network

CB1Inverse agonistSelective binding to CB1, effective blockade of its signalling with no effect on the other class A G-protein-coupled receptors (CB2 included) and suppression of the receptor's constitutive activity to the same extent as rimonabant (Heimann 2007); inhibition of agonist-induced receptor internalisation (Dodd 2010). No affinity value is published in these abstracts
  • Blocks or inhibits

The lower the cited value, the closer the target sits to Hémopressine: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Hémopressine.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1Inverse agonistno measured value cited

    Selective binding to CB1, effective blockade of its signalling with no effect on the other class A G-protein-coupled receptors (CB2 included) and suppression of the receptor's constitutive activity to the same extent as rimonabant (Heimann 2007); inhibition of agonist-induced receptor internalisation (Dodd 2010). No affinity value is published in these abstracts

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

Hemopressin is a nonapeptide of sequence PVNFKFLSH, derived from the alpha chain of haemoglobin, which has held a singular place in the history of the endocannabinoid system: that of the first peptide ligand of the CB1 receptor. Identified in 2003 as a metallopeptidase substrate and named after its hypotensive effect in the anaesthetised rat (Rioli 2003), it was characterised in 2007 as a selective antagonist and inverse agonist of CB1, blocking the receptor's constitutive activity as well as rimonabant does, without acting on the other family-A G protein-coupled receptors, CB2 included, with antinociceptive effects by intrathecal, intraplantar and oral routes (Heimann 2007). In 2010 it proved able to inhibit CB1 internalisation and to reduce night-time food intake in rats and mice, an effect absent in mice lacking CB1 (Dodd 2010). This history calls for an important reservation, which this wiki states rather than hides: the fact that a peptide from a cytosolic protein acts on a receptor does not prove it is an endogenous mediator, which would require establishing its brain synthesis, its secretion at sufficient levels and the regulation of one or the other (Gelman & Fricker 2010). The documented endogenous peptide of this family is the extended form, RVD-hemopressin or pepcan-12, produced from the pro-peptide pepcan-23, a negative allosteric modulator of CB1 and a positive one of CB2 (Bauer 2012; Petrucci 2017), while hemopressin shows poor plasma stability and is not bioavailable to the brain (Glasmacher & Gertsch 2021). Hemopressin therefore remains a documented pharmacological tool whose status as a physiological mediator is not settled.

History

Source
A peptide fragment derived from haemoglobin, not a lipid molecule like the classical endocannabinoids. Its endogenous character is precisely the contested point. A review devoted to peptides from cytosolic proteins frames the problem in terms of criteria: to count as a neuropeptide-like mediator, such a peptide must be synthesised in the brain, secreted at levels sufficient to produce its effects, and its synthesis or secretion must be regulated; acting on a receptor is not enough (Gelman & Fricker 2010). Work on the pepcan family has moreover established that the documented endogenous peptide of this series is the form extended by three residues, RVD-hemopressin or pepcan-12, released from a pro-peptide, pepcan-23 (Bauer 2012; Glasmacher & Gertsch 2021); that form has its own entry. Hemopressin itself shows poor plasma stability and is not bioavailable to the brain (Glasmacher & Gertsch 2021).

Biosynthetic pathway

In vivo

Hemopressin corresponds to a fragment of the alpha chain of haemoglobin, released by proteolytic cleavage: this is a peptide-generating route, unrelated to the lipid pathway that produces anandamide or 2-AG from membrane phospholipids. The peptide was in fact discovered as a substrate of metallopeptidases of neuropeptide metabolism (Rioli 2003). For the extended form the lineage is established: pepcan-23 acts as a pro-peptide and releases RVD-hemopressin (Glasmacher & Gertsch 2021). Nothing equivalent is demonstrated for the nonapeptide, whose in vivo production route remains undetermined.

Classification

Family, origin and source verification

Family

Endocannabinoid or related mediator › Peptide ligand

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

Hemopressin (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
Hemopressin (Hp, PVNFKFLSH)
Other names
Hemopressin · Hp · PVNFKFLSH

Identifiers

Formula
C₅₃H₇₇N₁₃O₁₂
CAS
568588-77-2
InChIKey
DUTLYPZZJJBEAJ-QISMNGAHSA-N
SMILES
CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]4CCCN4

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.